Delivery Order SPE2DB22D1106-SPE2DB23FERP9
Award Date 7/18/23
Potential Completion Date 7/19/23
Potential Value $31K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors with a ceiling value of $7,206.04. This non-competitive, firm fixed price delivery order was awarded on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a $21,976.95 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This is a firm fixed price, non-set-aside contract with a completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, chronic rhinosinusitis with nasal...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a $27,552.50 delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily indicated for moderate-to-severe atopic dermatitis, eosinophilic...
- The Defense Logistics Agency awarded a delivery order valued at $42,788.32 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 21, 2025, with completion expected by July 22, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $13,293.08. This firm fixed-price delivery order, which is effective through August 27, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a $62,204.43 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml pen injectors on November 25, 2025, with an ultimate completion date of November 26, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe...
- The Defense Logistics Agency awarded a $40,995.34 delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This competitively awarded, non-set-aside contract specifies firm fixed pricing with an ultimate completion date of April 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis,...
- The Defense Logistics Agency awarded a delivery order valued at $5,187.76 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injectors on November 20, 2025, with an ultimate completion date of November 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat moderate-to-severe...